2013
DOI: 10.1055/s-0033-1351099
|View full text |Cite
|
Sign up to set email alerts
|

Secondary Metabolites from Eupenicillium parvum and Their in Vitro Binding Affinity for Human Opioid and Cannabinoid Receptors

Abstract: Phytochemical investigation of the soil microfungus Eupenicillum parvum led to the isolation of two new compounds: a chromone derivative euparvione (1) and a new mycophenolic derivative euparvilactone (2), as well as thirteen known compounds. The structures of the new compounds were elucidated by means of extensive IR, NMR, and MS data and by comparison of data reported in the literature. The structure of the known compound 6 was confirmed by X-ray crystallography. Several isolated compounds were evaluated for… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
18
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 21 publications
(18 citation statements)
references
References 22 publications
(29 reference statements)
0
18
0
Order By: Relevance
“…Compounds evaluated in the assay were run in competition experiments using both cannabinoid receptor subtypes, CB1 and CB2 [25,26]. Cannabinoid receptor binding assays were performed under the following conditions: 10 μM of each compound was incubated with 0.5 nM [ 3 H]-CP 55,940, a potent cannabinoid agonist with affinity to both receptor subtypes, and 10 μg CB1 or CB2 membrane [26] for 90 min in a 96-well plate.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Compounds evaluated in the assay were run in competition experiments using both cannabinoid receptor subtypes, CB1 and CB2 [25,26]. Cannabinoid receptor binding assays were performed under the following conditions: 10 μM of each compound was incubated with 0.5 nM [ 3 H]-CP 55,940, a potent cannabinoid agonist with affinity to both receptor subtypes, and 10 μg CB1 or CB2 membrane [26] for 90 min in a 96-well plate.…”
Section: Methodsmentioning
confidence: 99%
“…Cannabinoid receptor binding assays were performed under the following conditions: 10 μM of each compound was incubated with 0.5 nM [ 3 H]-CP 55,940, a potent cannabinoid agonist with affinity to both receptor subtypes, and 10 μg CB1 or CB2 membrane [26] for 90 min in a 96-well plate. The reaction was terminated via rapid vacuum filtration through GF/C filters presoaked with 0.3% BSA using a Perkin Elmer 96-well Unifilter (Perkin Elmer Life Sciences Inc., Boston, Mass.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Compounds 1 – 22 were evaluated in competition binding with cannabinoid receptor subtypes, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), as previously described (Thomas et al 2005; León et al 2013). Also, these compounds were tested against the opioid receptor subtypes ( δ , κ and μ ) as previously described (León et al 2013).…”
Section: Methodsmentioning
confidence: 99%
“…Cannabiniod and opioid competitive radioligand binding assays were performed as previously described (Giacometti et al, 2013; Husni et al, 2014; León et al 2013; Tarawneh et al, 2013). Membrane evaluations and saturation experiments were performed for all receptors to determine optimal receptor concentration (varied from 1 µg to 25 µg protein) and radioligand dissociation constant (K d ) for the membrane (varied between 0.5 nM to 5 nM).…”
Section: Methodsmentioning
confidence: 99%